Method for Detecting Melanin-Containing Matter
US Patent 4,749,559
Filed on 1986-06-02
Filed on 1986-06-02
Cold Plate for Laboratory Use
US Patent 4,615,183
Filed on 1985-06-24
Filed on 1985-06-24
Synthesis of 2-hexadecanoylamino-4-nitrophenyl phosphoryl-choline-hydroxide
US Patent 4,082,781
Filed on 1976-06-04
Filed on 1976-06-04
Diagnostic test for Niemann-Pick Disease
US Patent 4,039,388
Filed on 1976-06-04
Filed on 1976-06-04
Immortal Line of Human Fetal Glial Cells
US Patent 4,707,448
Filed on 1984-10-04
Filed on 1984-10-04
SIMULTANEOUS DUAL-ENGERY COMPUTER ASSISTED TOMOGRAPHY
US Patent 4,247,774
Filed on 1978-06-26
Filed on 1978-06-26
DIAGNOSTIC TEST FOR GAUCHER'S DISEASE AND NIEMANN-PICK DISEASE
US Patent 3,531,374
Filed on 1967-12-27
Filed on 1967-12-27
Isolation of Glucocerebrosidase from Human Placental Tissue
US Patent 3,910,822
Filed on 1974-03-14
Filed on 1974-03-14
Identification and Development of Agents to Treat Glioblastoma and Other Tumors Over-expressing Nuclear Receptor CoRepressor
The National Institute of Neurological Disorders and Stroke (NINDS) and Lixte Biotechnology Holdings, Inc. (Lixte) are collaborating to identify and develop agents that target the Nuclear Receptor CoRepressor (N-COR) pathway. Dr. Zhengping Zhuang’s laboratory at NINDS has determined that several kinds of tumors, including glioblastomas and medulla blastomas, over-express N-CoR.
Use of Therapeutic Antibodies as a Novel Treatment for Multiple Sclerosis
Multiple sclerosis (MS) is a disease of the central nervous system in which the immune system attacks the brain and spinal cord, typically resulting in muscle weakness, problems with vision and coordination, pain, and, in some patients, cognitive impairments. The disorder affects approximately 400,000 people in the U.S. and more than 2.5 million people worldwide. Patients with relapsing forms of MS are currently treated with one of three FDA-approved interferon-beta agents or with glatiramer acetate.